Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

165
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
165
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

671
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
671
Pharmacovigilance01:19

Pharmacovigilance

1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

630
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
630

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.

Nature medicine·2026
Same author

Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis.

Diabetes, obesity & metabolism·2026
Same author

A polygenic risk score for peripheral artery disease and major adverse limb events.

European heart journal·2025
Same author

Polygenic Risk Score for Coronary Artery Disease Across the Spectrum of Atherosclerotic Disease.

European journal of preventive cardiology·2025
Same author

Galectin-3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE-TIMI 58.

ESC heart failure·2025
Same author

Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants.

Journal of the American College of Cardiology·2025

Related Experiment Videos

Clopidogrel response variability, resistance, or both?

Stephen D Wiviott1

  • 1TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. swiviott@partners.org

The American Journal of Cardiology
|November 14, 2006
PubMed
Summary
This summary is machine-generated.

Dual antiplatelet therapy is crucial for cardiovascular disease patients. Understanding and addressing variable responses to aspirin and clopidogrel is key to preventing ischemic events, especially after percutaneous coronary intervention.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard for cardiovascular disease.
  • Variable platelet response and resistance to clopidogrel can increase ischemic event risk.
  • Lack of standardized definitions for clopidogrel resistance causes clinical confusion.

Purpose of the Study:

  • To address key questions regarding clopidogrel resistance mechanisms and clinical implications.
  • To explore methods for measuring platelet function and defining adequate inhibition levels.
  • To investigate strategies for optimizing DAPT in non-responsive patients.

Main Methods:

  • Review of existing literature on antiplatelet therapy and platelet function.
  • Discussion of challenges in defining and measuring clopidogrel resistance.
  • Exploration of potential therapeutic modifications based on patient response.

Main Results:

  • Patients with lower clopidogrel response are at higher risk for ischemic events, particularly post-percutaneous coronary intervention.
  • Standardized definitions and reliable platelet function assays are needed for risk stratification.
  • Alternative antiplatelet strategies or dose adjustments may benefit non-responsive patients.

Conclusions:

  • Addressing variable platelet response to clopidogrel is critical for improving cardiovascular outcomes.
  • Development of standardized assays and definitions is essential for guiding therapy.
  • Personalized antiplatelet therapy based on individual response may enhance clinical efficacy and safety.